Novel Agents in the Treatment of Lung Cancer
Fourth Cambridge Conference - September 2006
This educational program was directed by Thomas J. Lynch, Jr, MD, Chief of Hematology/Oncology, Massachusetts General Hospital.
Educational Objectives
Following completion of this activity, participants should be able to:
- Discuss important attributes for leading classes of novel agents, including EGFR inhibitors, VEGF inhibitors, novel signal transduction inhibitors, other targeted therapies and combinations with chemotherapy.
- Assess current clinical results for these agents, including current data on safety and efficacy.
- Assess near-term clinical potential for patient care of each class of agents
Educational Grant Support
The program was supported by educational grants provided by: Genentech, AstraZeneca Pharmaceuticals, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Cell Therapeutics, Inc., EMD Pharmaceuticals, Millennium, sanofi-aventis U.S., and Telik.
Sponsorship
CME sponorship and program management are provided by InforMEDical.
The conference proceedings were published as a peer-reviewed CME supplement to Clinical Cancer Research, Vol 13 (15 Suppl), pp 1s-6s, Aug 2007.
Journal Website
(subscription may be required to access full journal supplement)
